HUNTINGTON NATIONAL BANK - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 171 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.

Quarter-by-quarter ownership
HUNTINGTON NATIONAL BANK ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2019$24,000
+500.0%
190
+280.0%
0.00%
Q2 2019$4,000
-33.3%
500.0%0.00%
Q1 2019$6,000
+20.0%
500.0%0.00%
Q4 2018$5,000
-16.7%
500.0%0.00%
Q3 2018$6,000
+50.0%
500.0%0.00%
Q2 2018$4,000
+33.3%
500.0%0.00%
Q1 2018$3,0000.0%500.0%0.00%
Q4 2017$3,0000.0%500.0%0.00%
Q3 2017$3,000
-50.0%
500.0%0.00%
Q2 2017$6,0000.0%500.0%0.00%
Q1 2017$6,000
+20.0%
500.0%0.00%
Q4 2016$5,000
-37.5%
500.0%0.00%
Q3 2016$8,000
+14.3%
500.0%0.00%
Q2 2016$7,000
-50.0%
500.0%0.00%
Q1 2016$14,000
+100.0%
500.0%0.00%
Q4 2015$7,000
-12.5%
500.0%0.00%
Q3 2015$8,000
-33.3%
500.0%0.00%
Q2 2015$12,000
-14.3%
500.0%0.00%
Q1 2015$14,000
+75.0%
500.0%0.00%
Q4 2014$8,000500.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2017
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 234,375$23,623,00022.67%
Boxer Capital, LLC 600,000$60,474,0007.47%
DLD Asset Management, LP 834,600$84,136,0005.77%
GREAT POINT PARTNERS LLC 200,000$20,158,0002.55%
BB BIOTECH AG 575,719$58,027,0001.86%
Elk Creek Partners, LLC 207,657$20,930,0001.74%
ALTRINSIC GLOBAL ADVISORS LLC 277,944$28,014,0001.34%
Sarissa Capital Management LP 54,000$5,442,0001.21%
QCM Cayman, Ltd. 2,181$220,0000.90%
Opus Point Partners Management, LLC 3,534$356,0000.78%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders